Selecta Biosciences (NASDAQ:SELB) Trading 19.4% Higher

Selecta Biosciences Inc (NASDAQ:SELB) rose 19.4% on Thursday . The stock traded as high as $1.85 and last traded at $2.15, approximately 6,117 shares changed hands during mid-day trading. A decline of 96% from the average daily volume of 143,584 shares. The stock had previously closed at $1.80.

SELB has been the topic of several research reports. ValuEngine upgraded Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday. Mizuho restated a “buy” rating and issued a $4.00 target price on shares of Selecta Biosciences in a research report on Friday, May 10th. Finally, Zacks Investment Research downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. Selecta Biosciences has a consensus rating of “Hold” and an average target price of $8.04.

The company’s 50-day moving average is $1.81.

Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Thursday, May 9th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.06. The firm had revenue of $0.01 million during the quarter. As a group, analysts expect that Selecta Biosciences Inc will post -1.35 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SELB. Two Sigma Investments LP increased its holdings in shares of Selecta Biosciences by 87.8% in the fourth quarter. Two Sigma Investments LP now owns 200,498 shares of the company’s stock valued at $533,000 after purchasing an additional 93,719 shares during the last quarter. Two Sigma Advisers LP increased its holdings in shares of Selecta Biosciences by 18.3% in the fourth quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock valued at $146,000 after purchasing an additional 8,500 shares during the last quarter. Polaris Venture Management Co. V L.L.C. increased its holdings in shares of Selecta Biosciences by 72.6% in the first quarter. Polaris Venture Management Co. V L.L.C. now owns 2,773,479 shares of the company’s stock valued at $6,573,000 after purchasing an additional 1,166,666 shares during the last quarter. FMR LLC increased its holdings in shares of Selecta Biosciences by 23.5% in the fourth quarter. FMR LLC now owns 345,046 shares of the company’s stock valued at $918,000 after purchasing an additional 65,623 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Selecta Biosciences by 17.9% in the fourth quarter. Geode Capital Management LLC now owns 175,308 shares of the company’s stock valued at $466,000 after purchasing an additional 26,568 shares during the last quarter. Institutional investors and hedge funds own 49.67% of the company’s stock.

About Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.

Featured Article: Put Option

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.